Literature DB >> 304386

Lassa immune serum.

A J Clayton.   

Abstract

Mesh：

Substances：

Year:  1977        PMID： 304386      PMCID： PMC2366682     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN： 0042-9686            Impact factor:   9.408


× No keyword cloud information.
  7 in total

1.  Antigenic properties of the arenaviruses.

Authors:  J Casals; S M Buckley; R Cedeno
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

2.  Lassa fever in Panguma Hospital, Sierra Leone, 1973-6.

Authors:  E Keane; H M Gilles
Journal:  Br Med J       Date:  1977-05-28

3.  Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases.

Authors:  T P Monath; M Maher; J Casals; R E Kissling; A Cacciapuoti
Journal:  Am J Trop Med Hyg       Date:  1974-11       Impact factor: 2.345

4.  Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972.

Authors:  P E Mertens; R Patton; J J Baum; T P Monath
Journal:  Am J Trop Med Hyg       Date:  1973-11       Impact factor: 2.345

5.  Indirect immunofluorescence for the diagnosis of Lassa fever infection.

Authors:  H Wulff; J V Lange
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

6.  Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus.

Authors:  S M Buckley; J Casals
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

7.  Diagnosis of Lassa fever and the isolation and management of patients.

Authors:  T P Monath; J Casals
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408
  7 in total
  10 in total

1.  A case of Lassa fever: clinical and virological findings.

Authors:  R T Emond; B Bannister; G Lloyd; T J Southee; E T Bowen
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-09

Review 2.  Native functionality and therapeutic targeting of arenaviral glycoproteins.

Authors:  Max Crispin; Antra Zeltina; Nicole Zitzmann; Thomas A Bowden
Journal:  Curr Opin Virol       Date:  2016-04-19       Impact factor: 7.090

Review 3.  Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.

Authors:  Ponraj Prabakaran; Zhongyu Zhu; Xiaodong Xiao; Arya Biragyn; Antony S Dimitrov; Christopher C Broder; Dimiter S Dimitrov
Journal:  Expert Opin Biol Ther       Date:  2009-03       Impact factor: 4.388

4.  Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain.

Authors:  P B Jahrling; C J Peters
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

5.  Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?

Authors:  Dimiter S Dimitrov; James D Marks
Journal:  Methods Mol Biol       Date:  2009

6.  A rapid research needs appraisal methodology to identify evidence gaps to inform clinical research priorities in response to outbreaks-results from the Lassa fever pilot.

Authors:  Louise Sigfrid; Catrin Moore; Alex P Salam; Nicola Maayan; Candyce Hamel; Chantelle Garritty; Vittoria Lutje; Brian Buckley; Karla Soares-Weiser; Rachel Marshall; Mike Clarke; Peter Horby
Journal:  BMC Med       Date:  2019-06-11       Impact factor: 8.775

Review 7.  The regulation and maturation of antiviral immune responses.

Authors:  J Lindsay Whitton; Mark K Slifka; Fei Liu; Alexander K Nussbaum; Jason K Whitmire
Journal:  Adv Virus Res       Date:  2004       Impact factor: 9.937

8.  Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.

Authors:  Laura Merson; Josephine Bourner; Sulaiman Jalloh; Astrid Erber; Alex Paddy Salam; Antoine Flahault; Piero L Olliaro
Journal:  PLoS Negl Trop Dis       Date:  2021-09-21

Review 9.  Passive antibody administration (immediate immunity) as a specific defense against biological weapons.

Authors:  Arturo Casadevall
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

10.  Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection.

Authors:  Rami Sommerstein; Lukas Flatz; Melissa M Remy; Pauline Malinge; Giovanni Magistrelli; Nicolas Fischer; Mehmet Sahin; Andreas Bergthaler; Sebastien Igonet; Jan Ter Meulen; Dorothée Rigo; Paolo Meda; Nadia Rabah; Bruno Coutard; Thomas A Bowden; Paul-Henri Lambert; Claire-Anne Siegrist; Daniel D Pinschewer
Journal:  PLoS Pathog       Date:  2015-11-20       Impact factor: 6.823
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.